Loading...
XASX
BXNDA
Market cap155mUSD
Jun 23, Last price  
0.10AUD
1D
3.09%
1Q
88.68%
IPO
-99.03%
Name

Bioxyne Ltd

Chart & Performance

D1W1MN
XASX:BXNDA chart
P/E
46.69
P/S
7.52
EPS
0.00
Div Yield, %
Shrs. gr., 5y
27.40%
Rev. gr., 5y
68.21%
Revenues
30m
+226.27%
1,684,644837,092674,5631,147,695751,897939,644123,275880,4972,391,7301,645,2382,024,2172,054,2912,151,3752,202,2822,259,2642,110,377463,6365,160,5389,325,02030,424,500
Net income
5m
P
-1,877,981-1,726,025-1,331,146-210,90680,1441,054-1,784,131-6,191,1131,190,827201,039223,846-765,752-1,311,840-1,265,882-593,095-495,725-494,022-1,939,970-13,325,0504,901,181
CFO
6m
P
-2,263,179-1,355,177-1,089,640-491,478152,072-76,369-4,695,374-971,704606,757-166,772348,852-424,048-1,855,355-1,390,36248,24953,134-506,811-1,131,026-3,559,9546,276,527

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Sydney, Australia, Bioxyne Limited is a life sciences and health company established in 1998. The firm dedicates itself to the research, development, marketing, and distribution of nutritional supplements and beauty products. Its operations are divided into wholesale and direct sales segments, reaching customers online, through partners, and directly across the United States and Asia. Bioxyne's diverse product line includes functional foods and cosmetic solutions, notably Progastrim for digestive and immune wellness, Progastrim plus Vitamin C for cold symptom relief, and proTract, specifically formulated for infant eczema (atopic dermatitis).
IPO date
Dec 14, 2000
Employees
16
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT